A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii.

Journal of Chemotherapy
Stamatis Karakonstantis

Abstract

The potential of A. baumannii for acquired resistance to last resort antibiotics (colistin and tigecycline) during treatment has important clinical implications, especially when dealing with patients failing to improve despite treatment with an active antimicrobial. However, the relevant literature remains scattered. Therefore, a systematic search was conducted in PubMed and Scopus. Several studies reported emergence of resistance to colistin or tigecycline during treatment, in most cases (86%) resulting in persistent or recurrent infections, especially in cases of emergent resistance without fitness cost. Lipopolysaccharide modification in the case of colistin and overexpression of efflux pumps in the case of tigecycline were the main mechanisms of resistance. Emergent colistin resistance is often associated with fitness cost which may result in re-emergence of the fitter and more virulent colistin susceptible strain after cessation of antibiotic pressure. Prospective studies are needed to determine the frequency of emergent resistance during treatment and its impact on patient outcomes.

References

Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Jian LiLisa Liolios
Jul 28, 2007·Pharmacotherapy·Gail E ReidNina M Clark
Jan 18, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kara B AnthonyEbbing Lautenbach
Feb 2, 2008·The Journal of Antimicrobial Chemotherapy·Miruna D David, Martin J Gill
Jun 18, 2010·The Journal of Antimicrobial Chemotherapy·Michael HornseyNeil Woodford
Sep 2, 2011·The Journal of Infectious Diseases·Jean-Marc RolainDidier Raoult
Sep 2, 2011·The Journal of Infectious Diseases·Rafael López-RojasJerónimo Pachón
Mar 24, 2012·The Journal of Antimicrobial Chemotherapy·Yun CaiNan Bai
Apr 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emanuele Durante-MangoniRiccardo Utili
Nov 6, 2013·Antimicrobial Agents and Chemotherapy·Alejandro BeceiroGermán Bou
Jan 30, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Zubair A QureshiYohei Doi
Oct 7, 2015·Antimicrobial Agents and Chemotherapy·Tze Peng LimLi Yang Hsu
Mar 30, 2016·International Journal of Antimicrobial Agents·Sibylle H LobRobert E Badal
Sep 15, 2016·The Journal of Antimicrobial Chemotherapy·Oren ZusmanMical Paul
Nov 16, 2016·International Journal of Antimicrobial Agents·Hyeon Jin ChoiKwan Soo Ko
Dec 21, 2016·Antimicrobial Agents and Chemotherapy·Crystal L JonesDaniel V Zurawski
Apr 26, 2017·International Journal of Antimicrobial Agents·Elias DahdouhMonica Suárez
Sep 7, 2017·Journal of Burn Care & Research : Official Publication of the American Burn Association·Tomas J SaunRobert Cartotto
Nov 12, 2017·International Journal of Antimicrobial Agents·Nadia JaidaneRémy A Bonnin
Nov 22, 2017·Antibiotics·Gabriela Jorge Da Silva, Sara Domingues
Dec 31, 2017·International Journal of Antimicrobial Agents·Konstantinos Z VardakasMatthew E Falagas
Aug 21, 2018·The Journal of Antimicrobial Chemotherapy·Mustapha M MustaphaYohei Doi
Nov 6, 2018·International Journal of Antimicrobial Agents·Garyfallia PoulakouNikolaos Zavras

❮ Previous
Next ❯

Citations

Apr 4, 2021·Pathogens·Meysam SarsharCecilia Ambrosi
Apr 4, 2021·Microorganisms·Corneliu Ovidiu VrancianuMariana Carmen Chifiriuc

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.